ClinicalTrials.gg
RecruitingNCT07662655Updated Jun 23, 2026

Percutaneous Pulmonary Artery Denervation (PADN) for the Treatment of Pulmonary Hypertension After Transcatheter Mitral Valve Edge-to-Edge Repair (M-TEER): A Prospective Cohort Study

An Early Phase 1 interventional study of Percutaneous Pulmonary Artery Denervation (PADN) and Control group (receiving standard medical therapy alone) in Pulmonary Hypertension and Pulmonary Hypertension Associated With HFpEF, sponsored by Xiamen Cardiovascular Hospital, Xiamen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by Xiamen Cardiovascular Hospital, Xiamen University · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 85 studies in Hypertension, Pulmonary with a site in China — 31 open to participants now, 36 under way, 5 of them phase 3. Hypertension, Pulmonary · China.

Planned enrollment
34th of 47
60 · median 100
Started
2026
with 4 others
Phase 1
5 of 85
2 open now
Primary completion
2028-05
later than 24 of 35 live
Registered
81st of 85
by date

Among the 85 studies in Hypertension, Pulmonary with a site in China, this one is the 34th largest by planned enrollment of the 47 interventional ones that give a count, is one of 5 that started in 2026, is one of 5 in phase 1, reaches primary completion later than 24 of the 35 other live ones, and was the 81st registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

31 of the 85 studies in Hypertension, Pulmonary with a site in China are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 163 Hypertension, Pulmonary studies recruiting now, 98 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 38 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Hypertension, Pulmonary with a site in China, or all of them as a file.
02

Study summary

this study aims to investigate the efficacy and safety of PADN therapy compared with standard medical therapy in patients diagnosed with pulmonary hypertension after M-TEER, thereby providing evidence for clinical treatment decision-making

03

Conditions studied

  • Pulmonary Hypertension
  • Pulmonary Hypertension Associated With HFpEF
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years and ≤80 years;
  2. Diagnosed with pulmonary hypertension (defined as mPAP >20 mmHg measured by right heart catheterization) at least 3 months after successful M-TEER, having received guideline-directed medical therapy (GDMT) for at least 2 months;
  3. No for PADN (e.g., anatomical abnormalities of the main pulmonary artery precluding catheter placement, known pulmonary artery stenosis, uncontrolled severe arrhythmias);
  4. Understands and is willing to sign the form and authorizes the use of health and study-related information;
  5. Willing to comply with the treatment and follow-up schedule required by the protocol

Exclusion criteria

Exclusion Criteria:

  1. Cardiac index (CI) \< 1.5 L/min/m²;
  2. Severe renal insufficiency ( rate (CrCL) \< 30 mL/min);
  3. (EF) \<30% on echocardiography;
  4. Severe hematological disease or severe bleeding tendency ( count \<10×10⁹/L; severe and extensive bleeding; suspected or confirmed intracranial hemorrhage);
  5. Systemic inflammatory disease, , tricuspid valve stenosis, pulmonary artery stenosis, and other cardiac diseases requiring surgical or interventional treatment;
  6. Acute systemic infectious disease;
  7. Poor general condition due to various systemic diseases;
  8. Pulmonary veno-occlusive disease;
  9. Cachexia;
  10. Diagnosed with WHO Group 1, 3, 4, or 5 pulmonary hypertension;
  11. Anticipated to undergo other surgical or interventional procedures within 6 months;
  12. \<12 months;
  13. Allergy to the drugs or metal materials used in the study;
  14. Women who are breastfeeding, pregnant, or planning to become pregnant within one year;
  15. Participation in another drug or medical device clinical trial within 3 months prior to screening;
  16. Any condition deemed unsuitable for participation in this clinical trial by the investigator. \|
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    PADN group (receiving PADN plus standard medical therapy)

    PADN group (receiving PADN plus standard medical therapy)

    Device: Percutaneous Pulmonary Artery Denervation (PADN)

  • Placebo comparator
    Control group (receiving standard medical therapy alone)

    Control group (receiving standard medical therapy alone)

    Drug: Control group (receiving standard medical therapy alone)

Interventions

  • DevicePercutaneous Pulmonary Artery Denervation (PADN)

    \*\*PADN Procedure Steps:\*\* 1. Non-Selective Pulmonary Artery Angiography 2. PADN Ablation Target Selection 3. Hemodynamic Assessment 4. Establishment of the PADN® RF Catheter Delivery Rail 5. PADN® RF Catheter Delivery 6. Performance of the PADN Procedure While maintaining the transseptal sheath position unchanged, the PADN® RF catheter is gently and slowly withdrawn and rotated (either clockwise or counterclockwise) to bring any three of the No. 2-9 electrodes into close apposition with the three target ablation points A, B, and C. . Temperature-controlled mode is recommended for radiofrequency ablation, with the ablation temperature set to 50°C and the total ablation time set to 150 seconds. The pulmonary artery radiofrequency ablation generator will automatically start calculating the effective ablation time (ET) once the ablation temperature reaches 45°C. Ablation at each target point is considered effective when the ET reaches at least 120 seconds. 7. Completion of the PADN

  • DrugControl group (receiving standard medical therapy alone)

    Control group (receiving standard medical therapy alone)

06

What researchers measure

Primary outcomes

  1. Clinical worsening event

    defined as the occurrence of any of the following: 1. Worsening heart failure symptoms requiring intravenous therapy (inotropes, diuretics, or vasodilators); 2. Heart failure-related rehospitalization; 3. Decrease in 6MWD from baseline by \>10% or \>30 meters; 4. Need for heart/lung transplantation; 5. All-cause death

    Time frame: From enrollment up to 12 months

Secondary outcomes

  1. Changes from baseline in pulmonary vascular resistance (right heart catheterization)

    Changes from baseline in pulmonary vascular resistance (PVR); Unit of measure: Wood units

    Time frame: From enrollment up to 12 months

  2. Changes from baseline in echocardiographic linear dimension parameters

    Changes from baseline in right atrial diameter (RAD), left atrial diameter (LAD), left ventricular internal diameter at end-diastole (LVIDd), left ventricular posterior wall thickness at end-systole (LVPWd), and tricuspid annular plane systolic excursion (TAPSE); Unit of measure: millimeters (mm)

    Time frame: From enrollment up to 12 months

  3. Changes from baseline in echocardiographic percentage functional indices

    * Parameters: Ejection fraction (EF), right ventricular fractional area change (RV-FAC) * Unit of measure: percentage (%)

    Time frame: From enrollment up to 12 months

  4. Changes from baseline in cardiac output (right heart catheterization)

    * Parameter: Cardiac output (CO) * Unit of measure: liters per minute (L/min)

    Time frame: From enrollment up to 12 months

  5. Changes from baseline in WHO functional class

    Time frame: From enrollment up to 12 months

  6. Changes from baseline in NT-proBNP/BNP

    Time frame: From enrollment up to 12 months

  7. Changes from baseline in 6-minute walk distance (6MWD)

    Time frame: From enrollment up to 12 months

  8. Changes from baseline in Short Form-36 (SF-36) Health Survey scale score

    The SF-36 scale ranges from 0 to 100, where higher scores indicate a better outcome (Minimum = 0, Maximum = 100).

    Time frame: From enrollment up to 12 months

  9. All-cause rehospitalization rate

    Time frame: From enrollment up to 12 months

  10. Incidence of worsening heart failure symptoms requiring intravenous therapy

    Time frame: From enrollment up to 12 months

  11. Heart failure-related rehospitalization rate

    Time frame: From enrollment up to 12 months

  12. Rate of need for heart/lung transplantation

    Time frame: From enrollment up to 12 months

  13. Changes from baseline in intracardiac pressure parameters (right heart catheterization)

    * Parameters: mean right atrial pressure (mRAP), right ventricular systolic pressure (RVSP), pulmonary artery systolic pressure (PASP), pulmonary artery diastolic pressure (PADP), mean pulmonary artery pressure (mPAP), pulmonary artery wedge pressure (PAWP) * Unit of measure: millimeters of mercury (mmHg)

    Time frame: From enrollment up to 12 months

  14. Changes from baseline in cardiac index (right heart catheterization)

    * Parameter: Cardiac index (CI) * Unit of measure: liters per minute per square meter (L/min/m²)

    Time frame: From enrollment up to 12 months

  15. Changes from baseline in pulmonary arterial compliance (right heart catheterization)

    * Parameter: Pulmonary arterial compliance (PAC) * Unit of measure: milliliters per millimeter of mercury (mL/mmHg)

    Time frame: From enrollment up to 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for May 2028, 23 months after the start.

Of 21 phase 1 interventional studies under Hypertension, Pulmonary, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's planned 23 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2026
First posted
Jun 23, 2026
StartActual
Jun 6, 2026
Primary completionEst.
May 31, 2028
CompletionEst.
Aug 31, 2028
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07662655
Lead sponsor
Xiamen Cardiovascular Hospital, Xiamen University
Responsible party
Xiang Chen (Principal Investigator, Xiamen Cardiovascular Hospital, Xiamen University) — Principal investigator
First posted
Jun 23, 2026
Start date
Jun 6, 2026
Primary completion
May 31, 2028 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Jun 23, 2026

Study contacts

Xiang CHEN, Dr
Contact
seanchenx@126.com
+8618033997788

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion